Parkinson Disease 6, Early Onset: Malacards - Research Articles, Symptoms, Drugs, Genes, Clinical Trials

Aliases & Classifications for Parkinson Disease 6, Early Onset

Sources:
⁴⁹OMIM, ¹¹diseasecard, ¹⁰Disease Ontology, ¹²DISEASES, ⁶⁷UniProtKB/Swiss-Prot, ²⁴GTR, ⁶⁵UMLS, ³⁴MedGen, ³⁶MeSH, ⁶¹The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Parkinson Disease 6, Early Onset:

Name: Parkinson Disease 6, Early Onset ⁴⁹ ¹¹

Parkinson Disease Autosomal Recessive Early-Onset Digenic Pink1/dj1 ⁶⁷ ²⁴

Autosomal Recessive Early-Onset Parkinson Disease Type 6 ⁶⁷ ²⁴

Early-Onset Parkinson Disease 6 ¹⁰ ¹²

Parkinson Disease 6 ⁶⁷ ²⁴

Park6 ¹⁰ ⁶⁷

Parkinson Disease 6, Autosomal Recessive Early-Onset ⁶⁵

Autosomal Recessive Early-Onset Parkinson Disease 6 ¹⁰

Parkinson Disease 6 Late-Onset Susceptibility to ⁶⁷

Parkinson Disease 6 Early-Onset ⁶⁷

Parkinsonism Young Adult Onset ⁶⁷

Characteristics:

HPO:

⁶¹

parkinson disease 6, early onset:
Onset and clinical course: slow progression, infantile onset
Inheritance: autosomal recessive inheritance

Classifications:

MalaCards categories:
Global: Genetic diseases, Rare diseases, Metabolic diseases
Anatomical: Neuronal diseases, Mental diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM⁴⁹ 605909

Disease Ontology¹⁰ DOID:0060369

MedGen³⁴ C1853833, C1970035, C2751533

MeSH³⁶ D010300, D020734

UMLS⁶⁵ C1853833

Summaries for Parkinson Disease 6, Early Onset

Sources:
¹⁰Disease Ontology, ⁶⁷UniProtKB/Swiss-Prot, ⁴⁹OMIM, ³³MalaCards
See all MalaCards sources

UniProtKB/Swiss-Prot:⁶⁷ Parkinson disease 6: A neurodegenerative disorder characterized by parkinsonian signs such as rigidity, resting tremor and bradykinesia. A subset of patients manifest additional symptoms including hyperreflexia, autonomic instability, dementia and psychiatric disturbances. Symptoms show diurnal fluctuation and can improve after sleep.

MalaCards based summary: Parkinson Disease 6, Early Onset, also known as parkinson disease autosomal recessive early-onset digenic pink1/dj1, is related to parkinson disease, late-onset and parkinson disease, juvenile, type 2, and has symptoms including resting tremor, postural instability and bradykinesia. An important gene associated with Parkinson Disease 6, Early Onset is PINK1 (PTEN Induced Putative Kinase 1), and among its related pathways are Pink/Parkin Mediated Mitophagy and Alpha-synuclein signaling. Affiliated tissues include kidney and colon, and related mouse phenotypes are cellular and nervous system.

Disease Ontology:¹⁰ A Parkinson's disease caused by mutations in the PINK1 gene located on chromosome 1p36.12.

Description from OMIM:⁴⁹ 605909

Related Diseases for Parkinson Disease 6, Early Onset

Sources:
²⁰GeneCards, ¹⁹GeneAnalytics
See all MalaCards sources

Diseases in the Parkinson Disease, Late-Onset family:

Parkinson Disease 7, Autosomal Recessive Early-Onset	parkinson disease 6, early onset
Parkinson Disease 19, Juvenile-Onset	Parkinson Disease 10
Parkinson Disease 16	Parkinson Disease 13
Parkinson Disease 11	Parkinson Disease 21
Parkinson Disease 18	Parkinson Disease 5
Parkinson Disease 4	Parkinson Disease 1
Parkinson Disease, Juvenile, Type 2	Parkinson Disease 8
Parkinson Disease 17	Parkinson Disease 20, Early-Onset
Parkinson Disease 15, Autosomal Recessive	Parkinson Disease 14, Autosomal Recessive
Parkinson Disease 12	Lrrk2-Related Parkinson Disease
Parkinson Disease Type 3	Parkinson Disease Type 9
Dnajc6-Related Parkinson Disease	Eif4g1-Related Parkinson Disease
Gigyf2-Related Parkinson Disease	Pla2g6-Related Parkinson Disease
Synj1-Related Parkinson Disease	Fbxo7-Related Parkinson Disease
Htra2-Related Parkinson Disease	Park7-Related Parkinson Disease
Snca-Related Parkinson Disease	Vps35-Related Parkinson Disease
Hereditary Late-Onset Parkinson Disease

Diseases related to Parkinson Disease 6, Early Onset via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 32)

id	Related Disease	Score	Top Affiliating Genes
1	parkinson disease, late-onset	28.3	LRRK2, MT-ND5, PARK2, PARK7, PINK1
2	parkinson disease, juvenile, type 2	11.2
3	visual epilepsy	10.4	MT-ND5, MT-ND6
4	mitochondrial encephalomyopathy lactic acidosis and stroke-like episodes	10.3	MT-ND5, MT-ND6
5	mitochondrial disorders	10.3	MT-ND5, MT-ND6
6	gemistocytic astrocytoma	10.3	MT-ND5, MT-ND6
7	lipid-rich carcinoma	10.3	MT-ND5, MT-ND6
8	progressive myoclonus epilepsy	10.3	MT-ND5, MT-ND6
9	eczematous dermatitis of eyelid	10.2	MT-ND5, MT-ND6
10	alcoholic cardiomyopathy	10.2	MT-ND5, MT-ND6
11	plexopathy	10.0	MT-ND5, MT-ND6
12	pde6d-related joubert syndrome	9.8	LRRK2, PARK7
13	essential tremor	9.7	LRRK2, PARK2
14	vascular erectile tumor	9.7	LRRK2, PARK2
15	polycystic kidney disease 2	9.6	LRRK2, PARK2
16	aspartylglucosaminuria	9.6	LRRK2, PARK2
17	acquired hyperkeratosis	9.6	ATP13A2, PARK2, PARK7
18	snrnp200-related retinitis pigmentosa	9.4	LRRK2, PARK2, PARK7
19	mast syndrome	9.4	LRRK2, PARK2, PARK7
20	supranuclear palsy, progressive atypical	9.4	LRRK2, PARK2, PARK7
21	parkinson disease 1	9.4	LRRK2, PARK2, PARK7
22	colon kaposi sarcoma	9.4	LRRK2, PARK2, PARK7
23	coenzyme q10 deficiency, primary, 1	9.3	ATP13A2, PARK2, PARK7, PINK1
24	pick disease	9.3	LRRK2, PARK2
25	iron-refractory iron deficiency anemia	9.2	ATP13A2, FBXO7, PARK2, PARK7
26	celiac disease 12	9.1	LRRK2, PARK2, PARK7, PINK1
27	central nervous system hereditary degenerative disease	9.1	LRRK2, PARK2, PARK7, PINK1
28	upper lip cancer	9.1	LRRK2, PARK2, PARK7, PINK1
29	atopic dermatitis	9.1	LRRK2, PARK2, PARK7, PINK1
30	epilepsy, progressive myoclonic 1b	8.5	ATP13A2, LRRK2, PARK2, PARK7, PINK1
31	adrenal cortical adenoma	8.5	ATP13A2, LRRK2, PARK2, PARK7, PINK1
32	parkinson disease 6, early onset	7.3	ATP13A2, FBXO7, LRRK2, MT-ND5, MT-ND6, PARK2

Graphical network of the top 20 diseases related to Parkinson Disease 6, Early Onset:

Symptoms for Parkinson Disease 6, Early Onset

Sources:
⁴⁹OMIM, ⁶¹The Human Phenotype Ontology, ⁶⁵UMLS
See all MalaCards sources

Symptoms by clinical synopsis from OMIM:

605909

Clinical features from OMIM:

605909

HPO human phenotypes related to Parkinson Disease 6, Early Onset:

(show all 11)

id	Description	HPO Source Accession
1	resting tremor	HP:0002322
2	postural instability	HP:0002172
3	bradykinesia	HP:0002067
4	rigidity	HP:0002063
5	hyperreflexia	HP:0001347
6	dystonia	HP:0001332
7	parkinsonism	HP:0001300
8	anxiety	HP:0000739
9	dementia	HP:0000726
10	depression	HP:0000716
11	urinary urgency	HP:0000012

UMLS symptoms related to Parkinson Disease 6, Early Onset:

bradykinesia, muscle rigidity

Drugs & Therapeutics for Parkinson Disease 6, Early Onset

Sources:
⁴⁴NIH Clinical Center, ⁴ClinicalTrials, ¹³DrugBank, ²⁶HMDB, ⁹DGIdb, ⁵³PharmGKB, ³⁰IUPHAR, ⁴⁷Novoseek, ¹BitterDB
See all MalaCards sources

Drugs for Parkinson Disease 6, Early Onset (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 9)

id

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

1

Pramipexole

approved, investigational

Phase 4

137

104632-26-0

59868, 119570

Synonyms:

(-)-Pramipexole

(6S)-6-N-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

(6S)-N(6)-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

(6S)-N6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

(S)-2-Amino-4,5,6,7-tetrahydro-6-(propylamino)benzothiazole

(S)-N 6-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine

104632-26-0

111GE001

2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole

2-amino-6-propylaminotetrahydrobenzothiazole

AC1L3P1T

BIDD:GT0250

C10H17N3S

CHEBI:8356

CHEMBL301265

CID119570

CPD000449298

D05575

DivK1c_006916

Furfuryl Acetate

HMS2051A21

HMS2090C15

KBio1_001860

KBio2_002340

KBio2_004908

KBio2_007476

KBioSS_002343

LS-40722

MLS000758250

MLS001423952

Mirapex

MolPort-003-849-957

NCGC00167441-01

Pramipexol

Pramipexol [Spanish]

Pramipexole

Pramipexole (USAN/INN)

Pramipexole 2HCl Monohydrate

Pramipexole Dihydrochloride Extended-Release

Pramipexole [USAN:INN]

Pramipexole hydrochloride

Pramipexolum

Pramipexolum [Latin]

SAM001247006

SBB070477

SMR000449298

SND-919

SUD919CL2Y

SpecPlus_000820

Spectrum5_001453

Spectrum_001838

U-98528E

pramipexole

2

Dopamine

approved

Phase 4

3084

62-31-7, 51-61-6

681

Synonyms:

(3H)-Dopamine

.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride

.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane

1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)

1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride

1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium

153C5321-5FEE-4B0B-8925-F388F0EEEBD1

2-(3,4-Dihydroxyphenyl)ethylamine

2-(3,4-dihydroxyphenyl)ethylamine

2-benzenediol

3,4-Dihydroxyphenethylamine

3,4-Dihydroxyphenethylamine hydrochloride

3,4-Dihydroxyphenylethylamine

3,4-dihydroxyphenethylamine

3-Hydroxtyramine

3-Hydroxytyramine

3-Hydroxytyramine Hydrobromide

3-Hydroxytyramine hydrochloride

4-(2-Aminoethyl)-1,

4-(2-Aminoethyl)-1,2-benzenediol

4-(2-Aminoethyl)-1,2-bezenediol

4-(2-Aminoethyl)-Pyrocatechol

4-(2-Aminoethyl)benzene-1,2-diol

4-(2-Aminoethyl)catechol

4-(2-Aminoethyl)pyrocatechol

4-(2-Aminoethyl)pyrocatechol hydrochloride

4-(2-aminoethyl)-pyrocatechol

50444-17-2

51-61-6

62-31-7 (HYDROCHLORIDE)

AC1L19S5

AC1Q54AX

AC1Q54AY

AKOS003790978

ASL 279

BIDD:ER0506

BPBio1_001123

BSPBio_001932

Biomol-NT_000001

C03758

CHEBI:18243

CHEMBL59

CID681

D07870

DB00988

Deoxyepinephrine

DivK1c_000780

Dopamin

Dopamina

Dopamina [INN-Spanish]

Dopamine

Dopamine (INN)

Dopamine (USAN)(*hydrochloride*)

Dopamine Hcl

Dopamine Hydrochloride

Dopamine [INN:BAN]

Dopaminum

Dopaminum [INN-Latin]

Dopastat

Dophamine

Dynatra

EINECS 200-110-0

HSDB 3068

Hydroxytyramin

Hydroxytyramine

IDI1_000780

IP 498

Intropin

Intropin [*hydrochloride*]

KBio1_000780

KBio2_001492

KBio2_002388

KBio2_002484

KBio2_004060

KBio2_004956

KBio2_005052

KBio2_006628

KBio2_007524

KBio2_007620

KBio3_001152

KBio3_002867

KBio3_002962

KBioGR_001129

KBioGR_002388

KBioGR_002484

KBioSS_001492

KBioSS_002393

KBioSS_002491

KW-3-060

L-DOPAMINE

L000232

LDP

LS-159

Lopac-H-8502

Lopac0_000586

Medopa (TN)

MolPort-001-641-000

NCGC00015519-01

NCGC00015519-08

NCGC00096050-01

NCGC00096050-02

NCGC00096050-03

NCGC00096050-04

NCGC00096050-05

NINDS_000780

NSC 173182

NSC169105

NSC173182

Oprea1_088821

Oxytyramine

Pyrocatechol, 4-(2-aminoethyl)- (8CI)

Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride

Revimine

Revivan

SPBio_001205

SPECTRUM1505155

ST048774

STK301601

Spectrum2_001023

Spectrum3_000406

Spectrum4_000525

Spectrum5_000945

Spectrum_001012

UNII-VTD58H1Z2X

UPCMLD0ENAT5885989:001

a-(3,4-Dihydroxyphenyl)-b-aminoethane

alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane

cMAP_000036

cMAP_000065

dopamine

hydroxytyramine

intropin

m-Hydroxytyramine hydrochloride

nchembio.105-comp9

nchembio.107-comp4

nchembio.284-comp1

nchembio.78-comp16

nchembio.89-comp3

nchembio705-8

nchembio801-comp8

3

Protective Agents

Phase 4

5651

4

Neurotransmitter Agents

Phase 4

14795

5

Dopamine Agonists

Phase 4

544

6

Antiparkinson Agents

Phase 4

1312

7

Dopamine Agents

Phase 4

3084

8

Antioxidants

Phase 4

2442

9

Fluorodeoxyglucose F18

Phase 2

356

Interventional clinical trials:

id	Name	Status	NCT ID	Phase
1	Study of (Mirapex) Pramipexole for the Early Treatment of Parkinsons Disease (PD)	Completed	NCT00321854	Phase 4
2	Development of a Novel 18F-DTBZ PET Imaging as a Biomarker to Monitor Neurodegeneration of PARK6 and PARK8 Parkinsonism	Completed	NCT01759888	Phase 2
3	A Trial of MitoQ for the Treatment of People With Parkinson's Disease	Completed	NCT00329056	Phase 2
4	Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families	Completed	NCT00273351	Phase 2
5	Parkin Mutations and Their Functional Consequences	Active, not recruiting	NCT00136721	Phase 1
6	Functional Characterization of Parkin + Patients	Terminated	NCT00142311	Phase 1
7	Hereditary Parkinson s Disease Natural History Protocol	Recruiting	NCT02511015
8	Genetic Study in Young Onset Parkinson's Disease	Active, not recruiting	NCT01529970
9	Early Parkinson's Disease (PD) Cross-Sectional	Terminated	NCT00817453

Search NIH Clinical Center for Parkinson Disease 6, Early Onset

Genetic Tests for Parkinson Disease 6, Early Onset

Anatomical Context for Parkinson Disease 6, Early Onset

Sources:
³³MalaCards
See all MalaCards sources

MalaCards organs/tissues related to Parkinson Disease 6, Early Onset:

³³

Kidney, Colon

Animal Models for Parkinson Disease 6, Early Onset or affiliated genes

Sources:
³⁸MGI
See all MalaCards sources

MGI Mouse Phenotypes related to Parkinson Disease 6, Early Onset:

³⁸

id	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	7.3	ATP13A2, LRRK2, MT-ND6, PARK2, PARK7, PINK1
2	nervous system	MP:0003631	7.0	ATP13A2, LRRK2, MT-ND6, PARK2, PARK7, PINK1

Publications for Parkinson Disease 6, Early Onset

Genes related to Parkinson Disease 6, Early Onset

Sources:
²⁰GeneCards, ⁴⁹OMIM, ⁵Clinvar, ⁶⁷UniProtKB/Swiss-Prot, ¹²DISEASES
See all MalaCards sources

Genes related to Parkinson Disease 6, Early Onset (1 elite genes):

- Elite gene

- Cancer Census gene in COSMIC

id	Symbol	Description	Score	Implication
1	PINK1	PTEN Induced Putative Kinase 1	1219.41	Molecular basis known ⁴⁹ Pathogenic ⁵ Causative variation ⁶⁷ DISEASES inferred ¹²
2	MT-ND6	Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 6	25.00	Risk factor ⁵
3	MT-ND5	Mitochondrially Encoded NADH:Ubiquinone Oxidoreductase Core Subunit 5	25.00	Risk factor ⁵
4	PARK2	Parkin RBR E3 Ubiquitin Protein Ligase	18.15	DISEASES inferred ¹²
5	PARK7	Parkinsonism Associated Deglycase	17.74	DISEASES inferred ¹²
6	ATP13A2	ATPase 13A2	17.09	DISEASES inferred ¹²
7	LRRK2	Leucine-Rich Repeat Kinase 2	16.28	DISEASES inferred ¹²
8	FBXO7	F-Box Protein 7	16.10	DISEASES inferred ¹²

Variations for Parkinson Disease 6, Early Onset

Sources:
⁶⁷UniProtKB/Swiss-Prot, ⁵Clinvar
See all MalaCards sources

UniProtKB/Swiss-Prot genetic disease variations for Parkinson Disease 6, Early Onset:

⁶⁷ (show all 22)

id	Symbol	AA change	Variation ID
1	PINK1	p.Gly309Asp	VAR_018994
2	PINK1	p.Cys92Phe	VAR_046568
3	PINK1	p.Ala168Pro	VAR_046575
4	PINK1	p.Pro196Leu	VAR_046577
5	PINK1	p.Ala217Asp	VAR_046578
6	PINK1	p.Glu240Lys	VAR_046581
7	PINK1	p.Leu268Val	VAR_046584
8	PINK1	p.His271Gln	VAR_046585
9	PINK1	p.Arg279His	VAR_046587
10	PINK1	p.Thr313Met	VAR_046589
11	PINK1	p.Leu347Pro	VAR_046593
12	PINK1	p.Cys388Arg	VAR_046596
13	PINK1	p.Glu417Gly	VAR_046599
14	PINK1	p.Arg464His	VAR_046605
15	PINK1	p.Leu489Pro	VAR_046607
16	PINK1	p.Cys125Gly	VAR_062773
17	PINK1	p.Ala280Thr	VAR_062774
18	PINK1	p.Leu369Pro	VAR_062775
19	PINK1	p.Gly386Ala	VAR_062776
20	PINK1	p.Arg407Gln	VAR_062778
21	PINK1	p.Gly409Val	VAR_062779
22	PINK1	p.Gln126Pro	VAR_064344

Clinvar genetic disease variations for Parkinson Disease 6, Early Onset:

⁵ (show all 15)

id	Gene	Variation	Type	Significance	SNP ID	Assembly	Location
1	PINK1	NM_032409.2(PINK1): c.620delG (p.Arg207Glnfs)	deletion	Pathogenic	rs756677845	GRCh37	Chr 1, 20964567: 20964567
2		NM_032409.2(PINK1): c.926G> A (p.Gly309Asp)	single nucleotide variant	Pathogenic	rs74315355	GRCh37	Chr 1, 20971132: 20971132
3		NM_032409.2(PINK1): c.813C> A (p.His271Gln)	single nucleotide variant	Pathogenic	rs28940284	GRCh37	Chr 1, 20971019: 20971019
4		NM_032409.2(PINK1): c.1311G> A (p.Trp437Ter)	single nucleotide variant	Pathogenic	rs74315356	GRCh37	Chr 1, 20975547: 20975547
5	PINK1	NM_032409.2(PINK1): c.736C> T (p.Arg246Ter)	single nucleotide variant	Pathogenic	rs74315357	GRCh37	Chr 1, 20966445: 20966445
6		NM_032409.2(PINK1): c.1040T> C (p.Leu347Pro)	single nucleotide variant	Pathogenic	rs28940285	GRCh37	Chr 1, 20972133: 20972133
7		NM_032409.2(PINK1): c.1570_1573dupTTAG (p.Asp525Valfs)	duplication	Pathogenic	rs730880302	GRCh37	Chr 1, 20977008: 20977011
8	PINK1	PINK1, 3-BP INS, 1602CAA	insertion	Pathogenic
9		NM_032409.2(PINK1): c.836G> A (p.Arg279His)	single nucleotide variant	Pathogenic	rs74315358	GRCh37	Chr 1, 20971042: 20971042
10		NM_005216.4(DDOST): c.807_5409del	deletion	Pathogenic		GRCh38	Chr 1, 20646970: 20651572
11		NM_032409.2(PINK1): c.938C> T (p.Thr313Met)	single nucleotide variant	Pathogenic	rs74315359	GRCh37	Chr 1, 20971144: 20971144
12	PINK1	NM_032409.2(PINK1): c.650C> A (p.Ala217Asp)	single nucleotide variant	Pathogenic	rs74315360	GRCh37	Chr 1, 20964597: 20964597
13		NM_032409.2(PINK1): c.1366C> T (p.Gln456Ter)	single nucleotide variant	Pathogenic	rs45539432	GRCh37	Chr 1, 20975602: 20975602
14	MT-ND6	m.14319T> C	single nucleotide variant	risk factor	rs199476110	GRCh37	Chr MT, 14319: 14319
15	MT-ND5	m.12397A> G	single nucleotide variant	risk factor	rs200890363	GRCh37	Chr MT, 12397: 12397

Expression for genes affiliated with Parkinson Disease 6, Early Onset

Sources:
¹⁷Gene Expression Omnibus DataSets
See all MalaCards sources

Search GEO for disease gene expression data for Parkinson Disease 6, Early Onset.

Pathways for genes affiliated with Parkinson Disease 6, Early Onset

Sources:
⁵²PathCards, ⁵⁷Reactome, ³⁹NCBI BioSystems Database, ⁵⁵QIAGEN, ³¹KEGG
See all MalaCards sources

Pathways related to Parkinson Disease 6, Early Onset according to GeneCards Suite gene sharing:

id	Super pathways	Score	Top Affiliating Genes
1	Pink/Parkin Mediated Mitophagy⁵⁷ Show member pathways Mitophagy⁵⁷	9.7	PARK2, PINK1
2	Alpha-synuclein signaling³⁹	9.5	PARK2, PARK7
3	Chks in Checkpoint Regulation⁵⁵ Show member pathways Parkinsons Disease Pathway⁵⁵ Estrogen-mediated S-Phase Entry⁵⁵ DNA Repair Mechanisms⁵⁵ G2-M Phase Transition⁵⁵ SREBP Proteolysis⁵⁵	9.2	PARK2, PARK7, PINK1
4	Parkinsons Disease Pathway³⁹	8.3	LRRK2, PARK2, PARK7, PINK1
5	Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.⁵⁷ Show member pathways Huntingtons disease³¹ Parkinsons disease³¹ The citric acid (TCA) cycle and respiratory electron transport⁵⁷ Respiratory electron transport⁵⁷ Complex I biogenesis⁵⁷ Oxidative phosphorylation³¹ Oxidative phosphorylation³⁹ Electron Transport Chain³⁹ Formation of ATP by chemiosmotic coupling⁵⁷	7.5	LRRK2, MT-ND5, MT-ND6, PARK2, PARK7, PINK1

GO Terms for genes affiliated with Parkinson Disease 6, Early Onset

Sources:
¹⁸Gene Ontology
See all MalaCards sources

Cellular components related to Parkinson Disease 6, Early Onset according to GeneCards Suite gene sharing:

id	Name	GO ID	Score	Top Affiliating Genes
1	neuron projection	GO:0043005	9.4	ATP13A2, MT-ND5
2	axon	GO:0030424	9.4	LRRK2, PARK7
3	mitochondrion	GO:0005739	8.6	FBXO7, LRRK2, PARK7

Biological processes related to Parkinson Disease 6, Early Onset according to GeneCards Suite gene sharing:

(show all 28)

id	Name	GO ID	Score	Top Affiliating Genes
1	regulation of protein ubiquitination	GO:0031396	10.1	PARK2, PINK1
2	positive regulation of mitochondrial fission	GO:0090141	10.1	PARK2, PINK1
3	regulation of synaptic vesicle transport	GO:1902803	10.1	PARK2, PINK1
4	cellular response to toxic substance	GO:0097237	10.1	PARK2, PINK1
5	regulation of mitophagy	GO:1903146	10.1	PARK2, PINK1
6	negative regulation of reactive oxygen species metabolic process	GO:2000378	10.1	PARK2, PINK1
7	negative regulation of hydrogen peroxide-induced neuron intrinsic apoptotic signaling pathway	GO:1903384	10.1	PARK7, PINK1
8	activation of protein kinase B activity	GO:0032148	10.1	PARK7, PINK1
9	positive regulation of mitochondrial electron transport, NADH to ubiquinone	GO:1902958	10.0	PARK7, PINK1
10	negative regulation of oxidative stress-induced cell death	GO:1903202	10.0	PARK7, PINK1
11	regulation of reactive oxygen species metabolic process	GO:2000377	10.0	PARK2, PINK1
12	macroautophagy	GO:0016236	10.0	PARK2, PINK1
13	positive regulation of sequence-specific DNA binding transcription factor activity	GO:0051091	10.0	PARK7, PINK1
14	positive regulation of protein kinase B signaling	GO:0051897	9.8	PARK7, PINK1
15	negative regulation of hydrogen peroxide-induced cell death	GO:1903206	9.8	LRRK2, PARK7
16	negative regulation of autophagosome assembly	GO:1902902	9.7	LRRK2, PINK1
17	cellular response to dopamine	GO:1903351	9.7	LRRK2, PARK2
18	regulation of canonical Wnt signaling pathway	GO:0060828	9.7	LRRK2, PARK2
19	protein localization to mitochondrion	GO:0070585	9.7	LRRK2, PARK2
20	negative regulation of cell death	GO:0060548	9.6	PARK2, PARK7
21	synaptic transmission, dopaminergic	GO:0001963	9.5	PARK2, PARK7
22	phosphorylation	GO:0016310	9.5	LRRK2, PINK1
23	mitophagy	GO:0000422	9.4	FBXO7, PARK2, PINK1
24	peptidyl-serine phosphorylation	GO:0018105	9.2	LRRK2, PINK1
25	cellular response to oxidative stress	GO:0034599	9.2	LRRK2, PARK7, PINK1
26	mitochondrion organization	GO:0007005	8.7	LRRK2, PARK2, PARK7, PINK1
27	response to oxidative stress	GO:0006979	8.7	LRRK2, PARK2, PARK7
28	negative regulation of protein phosphorylation	GO:0001933	8.4	LRRK2, PARK2, PARK7